Previous Close | 21.15 |
1-Year Change | 53.93% |
6-Months Change | 31.04% |
3-Months Change | 1.98% |
Moving Avg (50d) | 21.087 |
Moving Avg (200d) | 17.529 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.25B |
Beta (3-Years) | 1.1 |
Revenue Growth (ttm) | 81.69% |
Net Profit Margin (ttm) | 17.81% |
Return On Assets (ttm) | 15.01% |
EPS (ttm) | 0.53 |
PE Ratio (ttm) | 39.91 |
Dividend Yield | % |
Asset Description: | Catalyst Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-23 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
21.573 | 22.207 | 22.63 | 23.265 | 24.322 | 25.38 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |